Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time: June 2, 2021; 5:15-9:00 p.m.
Minutes prepared by: Umang Patel and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD.; Tsewang Ngodup, MD.; Tim Cernohous, PharmD.; Kyle Lehenbauer, MD.; Mary Mescher Benbenek, APRN, PhD.; Kelly Ruby, PharmD.; Monica Brands, RPh.; Ramona Powell, PharmD.; Margaret Artz, RPh., PhD.; Michael Sprehe, MD.; Katherine Montag Schafer, PharmD.; Kathryn Lombardo, MD.
- **Member absent:** James Phillips, MD.
- **DHS staff present:** Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.
- **Others in attendance:** Ariane Casey, PharmD.; Umang Patel, PharmD.; Naana Osei-Boateng, PharmD.

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- Minutes from the February 2021 meetings were reviewed and accepted as presented.

DHS Housekeeping

- DFC welcomed newly appointed member, Katherine Montag Schafer, PharmD.
- DFC welcomed reappointed members: Monica Brands, RPh.; Kathryn Lombardo, MD.; Kelly Ruby, PharmD.; Michael Sprehe, MD., MPH.
- Dave Hoang informed the meeting the conflict of interest disclosure form has been revised and posted.

Old Business – None

New Business – None

- The committee discussed the Nonpreferred PA Criteria and recommended the policy by a unanimous vote.
- The committee discussed the Consent Agenda Policy and recommended the policy by a unanimous vote.
Preferred Drug List Review

- The committee discussed the Acne Agents, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - DIFFERIN GEL (TOPICAL), TRETINOIN CREAM (TOPICAL), and TRETINOIN GEL (AVITA, RETIN-A) (TOPICAL) to be moved to the PDL as NONPREFERRED
  - RETIN-A CREAM (TOPICAL) and RETIN-A GEL (TOPICAL) to be moved to the PDL as PREFERRED
  - AZELEX to be removed from the PDL

- The committee discussed the Analgesics, Narcotics Long therapeutic class and recommended the following to the department by a unanimous vote:
  - HYDROCODONE ER (HYSINGLA ER) (ORAL), HYDROCODONE ER (ZOHYDRO ER) (ORAL), METHADONE CONC (ORAL), and METHADONE SOLUTION (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Androgenic Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - TESTOSTERONE GEL (FORTESTA) (TRANSDERM) and TESTOSTERONE GEL (TESTIM) (TRANSDERM) to be added to the PDL as NONPREFERRED

- The committee discussed Angiotensin Modulator Combinations therapeutic class and recommended the following to the department by a unanimous vote:
  - PRESTALIA (ORAL) will be removed from the PDL
  - TRANDOLAPRIL/VERAPAMIL (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Angiotensin Modulator therapeutic class and recommended the following to the department by a unanimous vote:
  - ENTRESTO (ORAL) to be moved to the PDL as PREFERRED
  - MOEXIPRIL HCTZ (ORAL) and MAVIK (ORAL) to be removed from PDL

- The committee discussed the Antibiotics, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - XEPI (TOPICAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antibiotics, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  - ELIQUIS (ORAL) AND ELIQUIS DOSE PACK (ORAL) to be moved to the PDL as PREFERRED

- The committee discussed the Antidepressants, Other therapeutic class and recommended the following to the department by a unanimous vote:
  - BUPROPION XL (FORFIVO XL) (AG) (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antiemetic/Antivertigo Agents therapeutic class and recommended the following to the department by a unanimous vote:
  - GIMOTI (NASAL), METOCLOPRAMIDE ODT (ORAL), AND VARUBI (ORAL) to be added to the PDL as NONPREFERRED
• The committee discussed the Antifungals, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  o KERYDIN (TOPICAL) and TAVABOROLE (TOPICAL) to be added to the PDL as NONPREFERRED
  o KETACONAZOLE CREAM (TOPICAL) to be added to the PDL as PREFERRED

• The committee discussed the Antihistamines, Minimally Sedating therapeutic class and recommended the following to the department by a unanimous vote:
  o CETIRIZINE CHEWABLE OTC (ORAL) to be moved on the PDL to NONPREFERRED
  o Remove the OTC footnote from the PREFERRED section as the footnote was from the legacy Fee-for-Service Preferred Drug List and is no longer applicable to the Uniform Preferred Drug List

• The committee discussed the Antimigraine Agents, Other therapeutic class and recommended the following to the department by a unanimous vote:
  o AJOVY AUTOINJECTOR (SUBCUTANEOUS) and UBRELVY (ORAL) to be added to the PDL as PREFERRED
  o NURTEC ODT (ORAL), REYVOW (ORAL) AND VYEPTI (INTRAVENOUS) to be added to the PDL as NONPREFERRED

• The committee discussed the Antimigraine Agents, triptans therapeutic class and recommended the following to the department by a unanimous vote:
  o IMITREX (NASAL) to be moved to the PDL as PREFERRED
  o IMITREX KIT (SUBCUTANEOUS) AND IMITREX VIAL (SUBCUTANEOUS) to be added to the PDL as PREFERRED
  o SUMATRIPTAN (NASAL) to be moved to the PDL as NONPREFERRED
  o SUMATRIPTAN (NASAL), SUMATRIPTAN KIT (SUBCUTANEOUS), SUMATRIPTAN DISP SYRINGE (SUBCUTANEOUS), SUMATRIPTAN VIAL (SUBCUTANEOUS), and ZOLMITRIPTAN SPRAY (AG) (NASAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Antiparasitics, Topical therapeutic class and recommended the following to the department by a unanimous vote:
  o CROTAN (TOPICAL) and EURAX LOTION (TOPICAL) to be added to the PDL as NONPREFERRED

• The committee discussed the AntiParkinson’s Agents therapeutic class and recommended the following to the department by a unanimous vote:
  o CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL) to be added to the PDL as PREFERRED
  o KYNMOBI (SUBLINGUAL), ONGENTYS (ORAL), STALEVO (ORAL), AND TOLCAPONE (ORAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Antipsychotics therapeutic class and recommended the following to the department by a unanimous vote:
  o ASENAPINE (SUBLINGUAL) AND ASENAPINE (AG) (SUBLINGUAL) to be added to the PDL as NONPREFERRED
• The committee discussed the Beta Blockers therapeutic class and recommended the following to the department by a unanimous vote:
  o ATENOLOL/CHLORTALIDONE (ORAL), BISOPROLOL HCTZ (ORAL), METOPROLOL/HCTZ (ORAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Bladder Relaxant Preparations class and recommended the following to the department by a unanimous vote:
  o VESICARE LS (ORAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Bone Resorption Suppression and Related Agents class and recommended the following to the department by a unanimous vote:
  o FORTEO (SUBCUTANEOUS) to be moved on the PDL to NONPREFERRED
  o TERIPARATIDE (SUBCUTANEOUS) to be added to the PDL as PREFERRED

• The committee discussed the Bronchodilators, Beta Agonist and recommended the following to the department by a unanimous vote:
  o ALBUTEROL HFA (PROAIR HFA) (INHALATION), ALBUTEROL HFA (PROAIR HFA) (AG) (INHALATION), ALBUTEROL HFA (PROVENTIL HFA) (INHALATION), ALBUTEROL HFA (PROVENTIL HFA) (AG) (INHALATION), ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION), PROAIR RESPICLICK (INHALATION), PROVENTIL HFA (INHALATION) to be moved on the PDL to NONPREFERRED

• The committee discussed the Calcium Channel Blockers class and recommended the following to the department by a unanimous vote:
  o MATZIM LA (ORAL) to be moved on the PDL to NONPREFERRED

• The committee discussed the Cephalosporins and Related Antibiotic class and recommend the following to the department by a unanimous vote:
  o CEPHALEXIN TABLET (ORAL) to be added to the PDL as NONPREFERRED
  o CEDAX CAPSULE (ORAL), CEDAX SUSPENSION (ORAL), CEFDINIR SUSPENSION (ORAL) (DUPLICATE LISTING LINE), AUGMENTIN 125 SUSPENSION (ORAL), AUGMENTIN 250 SUSPENSION (ORAL), CEFTIN SUSPENSION (ORAL), CEFTIN TABLET (ORAL), DAXBIA (ORAL) to be removed from the PDL
  o SUPRAX SUSPENSION (ORAL) to be moved from PREFERRED to NONPREFERRED
  o SUPRAX CAPSULE (ORAL) OR CEFIXIME CAPSULE (ORAL) to be given PREFERRED status

• The committee discussed the COPD Agents class and recommended the following to the department by a unanimous vote:
  o ANORO ELLIPTA (INHALATION) to be moved on the PDL to PREFERRED
  o DUAKLIR PRESSAIR (INHALATION) to be added to the PDL to NONPREFERRED
• The committee discussed the Cytokine and CAM Antagonists class and recommended the following to the department by a majority vote with one member abstaining:
  o ENBREL MINI CARTRIDGE (SUBCUTANEOUS) and ENBREL VIAL (SUBCUTANEOUS) to be added to the PDL to PREFERRED
  o ACTEMRA SYRINGE (SUBCUTANEOUS), ACTEMRA VIAL (INJECTION), OLUMIANT (ORAL), SKYRIZI (SUBCUTANEOUS), and XELJANZ SOLUTION (ORAL) to be added to the PDL to NONPREFERRED
  o ACTEMRA AUTOINJECTOR wording being changed to ACTEMRA PEN (SUBCUTANEOUS)
  o The class will be reviewed by the DFC at a future meeting regarding the possibility of an addition of a preferred oral drug.

• The committee discussed the Diabetes Meters, Continuous class AND Transmitters and Sensors and recommended the following to the department by a unanimous vote:
  o DIABETES METERS, CONTINUOUS CLASS: FREESTYLE LIBRE 2 READER to be added to the PDL to PREFERRED
  o TRANSMITTORS AND SENSORS: FREESTYLE LIBRE 2 SENSOR to be added to the PDL to PREFERRED

• The committee discussed the Glucocorticoids, Inhaled class and recommended the following to the department by a majority vote with 1 member abstaining:
  o FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION) and FLUTICASONE/SALMETEROL (ADVAIR) (INHALATION) to be moved to the PDL to NONPREFERRED
  o BREZTRI AEROSPHERE (INHALATION) to be added to the PDL to NONPREFERRED

• The committee discussed the Hypoglycemics, Incretin Mimetics/Enhancers class and recommended the following to the department by a unanimous:
  o BYDUREON PENS (SUBCUTANEOUS) to be removed from the PDL
  o BYDUREON BCISE (SUBCUTANEOUS) to be moved on the PDL to PREFERRED

CONSENT AGENDA ITEMS
• Katherine Montag Schafer requested that Antifungal, Oral class be moved to the full agenda for discussion and a separate vote.

• The committee recommended that all items in the Consent Agenda be adopted as proposed EXCEPT the Antifungal, Oral class by a unanimous vote.

• The committee discussed and recommended that Antifungals, Oral class be passed with no changes by a unanimous vote.

Adjournment
• The meeting was adjourned at approximately 9:25 p.m. Central Time.